Galenica AG, headquartered in Switzerland (CH), is a leading player in the healthcare and pharmaceutical industry, primarily focusing on the distribution and retail of pharmaceuticals and healthcare products. Founded in 1927, Galenica has established itself as a trusted name, with significant operations across Switzerland and a growing presence in Europe. The company excels in providing a comprehensive range of services, including logistics, pharmacy management, and health-related solutions, which are distinguished by their commitment to quality and innovation. Galenica's unique approach integrates digital solutions with traditional pharmacy services, enhancing customer experience and operational efficiency. With a strong market position, Galenica has achieved notable milestones, including strategic partnerships and expansions that reinforce its reputation as a reliable healthcare provider. The company's dedication to improving patient outcomes and its robust portfolio of products and services make it a key player in the evolving healthcare landscape.
How does Galenica's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Galenica's score of 54 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Galenica reported total greenhouse gas emissions of approximately 7,228,000 kg CO2e, with Scope 2 emissions accounting for about 682,000 kg CO2e and upstream transportation and distribution under Scope 3 contributing approximately 4,257,000 kg CO2e. In 2023, the company recorded total emissions of about 8,774,000 kg CO2e, with Scope 3 emissions from upstream transportation and distribution at approximately 3,375,000 kg CO2e. Galenica has set ambitious climate commitments, aiming to reduce its operational greenhouse gas emissions (Scope 1 and 2) by 25% by 2025 and by 50% by 2030, using 2021 as the base year. Furthermore, the company is committed to achieving net zero emissions across all scopes by 2050, aligning with Switzerland's national climate goals. These initiatives reflect Galenica's dedication to sustainability and reducing its carbon footprint in the pharmaceutical and healthcare sector.
Access structured emissions data, company-specific emission factors, and source documents
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|
Scope 1 | 3,008,000 | - | 0,000,000 | - | - | - | - | - |
Scope 2 | 1,771,000 | 0,000,000 | 0,000,000 | - | - | - | - | 000,000 |
Scope 3 | 3,040,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Galenica is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.